Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.32 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28128144 | 0.97 | MALT1 (0.36) | MALT1HSP90AA1HDAC8NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL6192480 | 0.97 | MALT1 (0.36) | MALT1HSP90AA1HDAC8NOS3NOS2 | |
| Biphenyl SCHEMBL27729747 | 0.84 | KIF11 (0.50) | ALDH1A1KDM4ELMNATSHRMAPT | |
| SCHEMBL30397418 | 0.84 | MALT1 (0.32) | MALT1 | |
| Trifluoroacetic Acid SCHEMBL38653278 | 0.83 | L3MBTL1 (0.40) | ALDH1A1KDM4ELMNABLMP4HTM | |
| SCHEMBL30995275 | 0.79 | MALT1 (0.34) | MALT1 | |
| SCHEMBL28204675 | 0.78 | — | — | |
| SCHEMBL28898005 | 0.77 | CYP2A6 (0.40) | ALDH1A1CYP1A2HIF1ATSHRMAPT | |
| Ammonia Solution, Strong SCHEMBL28127895 | 0.76 | — | — | |
| SCHEMBL28127892 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 810 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688154-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - Portela & Ca., S.A. (PT) | 2026-02-11 | — | — | EP | claimed |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | claimed |
| CN-120040371-A | Compound capable of degrading MYC in targeted manner and application thereof | 中国医学科学院医药生物技术研究所 | 2025-05-27 | — | — | CN | claimed |
| EP-4543870-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-04-30 | — | — | EP | claimed |
| CN-119798168-A | Preparation method of 5-bromo-2-trifluoromethyl pyrimidine | 金凯(辽宁)生命科技股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| WO-2025023851-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | claimed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | claimed |
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | claimed |
| CN-117886807-A | Ferulic acid derivative containing 1,3, 4-oxadiazole and trifluoromethyl pyrimidine | 贵阳学院 | 2024-04-16 | — | — | CN | claimed |
| WO-2024057001-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCERS | Benevolentai Cambridge Limited (GB) | 2024-03-21 | — | — | WO | claimed |
| EP-2245017-A2 | NOVEL HETEROCYCLES | Orchid Research Laboratories Limited (IN) | 2010-11-03 | — | — | EP | claimed |
| WO-2009095773-A2 | NOVEL HETEROCYCLES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-06 | — | — | WO | claimed |
| US-20090118316-A1 | Methods for Augmenting Bone | PFZER INC. | 2009-05-07 | — | — | US | claimed |
| EP-1765461-A1 | PYK2 INHIBITORS FOR STIMULATION OF OSTEOBLAST FUNCTION | Pharmacia & Upjohn Company LLC (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2005123191-A1 | PYK2 INHIBITORS FOR STIMULATION OF OSTEOBLAST FUNCTION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-12-29 | — | — | WO | claimed |
| EP-1351691-A4 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004108706-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2004-12-16 | — | — | WO | claimed |
| EP-1351691-A1 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| US-20030069239-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-10 | — | — | US | claimed |
| WO-2002047690-A1 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-06-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | MALT1 3231/4885HSP90AA1 789/4885HDAC8 1381/4885 |
| US-20090118316-A1 | Methods for Augmenting Bone | PTK2, PHKA2, BMP2K | MALT1 4682/4885HSP90AA1 3476/4885HDAC8 4006/4885 |
| US-20030069239-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof | API5, CASP2, APAF1 | MALT1 291/4885HSP90AA1 1802/4885HDAC8 467/4885 |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | MALT1 2880/4885HSP90AA1 3958/4885HDAC8 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.